Drug Profile
Research programme: serotonin 5HT1a agonist - Cenomed
Alternative Names: CBE; CM-2,385Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Cenomed BioSciences
- Class
- Mechanism of Action 5-HT1A serotonin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Nausea and vomiting
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Nausea and vomiting in USA
- 21 Oct 2009 Preclinical trials in Nausea and vomiting in USA (unspecified route)